Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
#FRIDAYREAD Patients with certain #autoimmunediseases develop immunoglobulin isotype or subclass #autoantibodies (IgG, IgA, IgG1, IgG). Skin diseases can be associated with IgE autoantibodies -atopic #dermatitis #chronicurticaria. #patientstratification
Comprehensive overview of autoantibody isotype and subclass distribution
The presence of autoreactive antibodies is a hallmark of many autoimmune diseases. The effector functions of (auto)antibodies are determined by their ...
ow.ly
At Oncimmune, our team comes together to provide autoantibody biomarker insights to support clients in better understanding the immune response to therapies, improve trial outcomes and develop safer treatments. #TeamOncimmune #ImmunoINSIGHTS #Biomarkers https://bit.ly/3V2Do2r
Scientists at #Oncimmune rely on #Luminex xMAP® Technology for high throughput to detect thousands of antibodies in hundreds of samples #Oncimmune #Biomarkers #ImmuneBiomarkers #Autoantibodies #ImmunoAssays #Multiplex
https://bit.ly/3Sjs6o6
#FRIDAYREAD A review of current knowledge on #autoantibodies #breastcancer cancer. Their full potential for prognosis & therapeutic response prediction has not been established. Multiplexing of autoantibodies will be required to improve their sensitivity.
Autoantibodies as biomarkers for breast cancer diagnosis and prognosis
Breast cancer is the most common cancer in women worldwide and is a substantial public health problem. Screening for breast cancer mainly relies on ma...
bit.ly
Oncimmune is proud to celebrate #WorldScienceDay
and committed to support clients and collaborators to
improve the understanding of the immune system
http://bit.ly/3fGnzyy #TeamOncimmune #ImmunoINSIGHTS
#Biomarkers #Autoantibodies
#FRIDAYREAD The relation between anti-nuclear #autoantibodies & the development of immune-related adverse events in #cancer patients treated wt #checkpointinhibitors. They found de novo ANA #autoantibodies were associated with higher severe irAE rates
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
Immune-related adverse events (irAEs) are unpredictable autoimmune-like toxicities induced by immune checkpoint inhibitors (ICI). irAEs are a conseque...
bit.ly
It’s been great to have @OncimmuneECDT as part of our UK #delegation at #bioeurope2022. 🇬🇧
#Networking #conference #lifesciences
NOW ENROLLING: Advance your #immunooncology research & gain antibody #biomarker insights. Enroll by Jan 15, 2023 & test up to 30 samples free of charge https://bit.ly/3fa92ew #ImmunoINSIGHTS #Autoantibodies #Breastcancer #Ovariancancer #Lungcancer #Prostatecancer
Gallery
